๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Immune Thrombocytopenia
Clinical trial register · China

Immune Thrombocytopenia Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Tianjin 16 Beijing 5 Wuhan 3 Jinan 2 Qingdao 1
Narrow the registerReset
Recruitment status
Phase
Site location
Tianjin16 Beijing5 Wuhan3 Jinan2 Qingdao1
All 13 locations
Target enrolment
to

Immune Thrombocytopenia trials in China

25 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Eltrombopag Plus Telitacicept vs. Eltrombopag Alone for Steroid-refractory/Relapsed ITP
NCT07687134Immune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
40
Tianjin
2026-07-10
Recruiting
Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
NCT07657793Systemic Lupus Erythematosus, Immune Thrombocytopenia
Chinese SLE Treatment And Research Group
Phase 2/3
164
Beijing
2026-06-07
Not yet open
ATRA for Management of Primary ITP
NCT07597395Immune Thrombocytopenia
Peking University People's Hospital
Phase 3
192
Beijing
2026-05-30
Not yet open
Universal STAR-T Cell Injection in R/R Autoimmune Diseases.
NCT07599280Immune Thrombocytopenia
Jian Zhu
Phase 1
6
Haidian
2026-05-11
Recruiting
Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT07362238Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
122
Tianjin
2026-03
Recruiting
Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07362199Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-03
Recruiting
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07234019Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
160
Tianjin
2026-01-28
Recruiting
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
NCT07297563Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
160
Tianjin
2026-01-20
Recruiting
Phase I Study of SHR-2173 Injection in Patients With Primary Immune Thrombocytopenia
NCT07206758Immune Thrombocytopenia
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 1
10
Wuhan
2025-11-12
Recruiting
Anti-CD38 Antibody Treating Elderly Patients With Primary Immune Thrombocytopenia (ITP)
NCT07063199Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2025-08
Not yet open
The Combination of Upadacitinib and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia
NCT07064889Immune Thrombocytopenia
Peking University People's Hospital
Phase 2
132
Beijing
2025-07-30
Recruiting
A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia
NCT06776510Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
20
Tianjin
2025-01-15
Recruiting
Longitudinal Cohort of Thrombosis and Hemostasis Diseases
NCT06727669Immune Thrombocytopenia, Thrombotic Thrombocytopenic Purpura, Hemophilia A, Acquired, Disseminated Intravascular Coagulation
Peking University People's Hospital
Observational
3,000
Beijing, Zhengzhou, Chongqing
2024-11-01
Recruiting
Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)
NCT06519565Immune Thrombocytopenia
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase EARLY_PHASE1
6
Wuhan
2024-08-20
Recruiting
Anti-CD38 Antibody Treating Children With Primary Immune Thrombocytopenia (ITP)
NCT06838962Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2024-08-01
Recruiting
TPO-RA Treatment on Immune Tolerance Induction of ITP Patients With Sustained Platelet Recovery After Treatment Termination
NCT06478537Immune Thrombocytopenia
Peking Union Medical College Hospital
Phase 2
56
Beijing
2024-06-20
Recruiting
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
NCT06281327Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2024-03-01
Active, closed
A Randomized, Double-blind, Placebo-controlled, and Multi-center Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia
NCT06199089Immune Thrombocytopenia, Treatment
DrugCM313
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
45
Tianjin
2024-01-16
Recruiting
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06168851Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2023-12-28
Recruiting
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)
NCT06094881Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
60
Tianjin
2023-12-01
Recruiting
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia
NCT05995054Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
110
Tianjin
2023-08-28
Recruiting
A Prospective, One-arm and Open Clinical Study of Zanubrutinib in the Treatment of Immune Thrombocytopenia
NCT05214391Immune Thrombocytopenia, Treatment
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
30
Tianjin
2022-02-15
Recruiting
Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
NCT04993885Immune Thrombocytopenia, Autoantibodies, Evan Syndrome, Connective Tissue Diseases
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
52
Tianjin
2021-09-01
Active, closed
A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP
NCT05023915Immune Thrombocytopenia
Shandong University
Phase 2
106
Jinan, Qingdao
2021-08-21
Active, closed
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
NCT04562766Immune Thrombocytopenia
Principia Biopharma, a Sanofi Company
Phase 3
232
Wuhan, Shenyang, Xi'an, Jinan, Tianjin, Kunming, Hangzhou, Hefei
2020-12-14
Rows per page Showing 1–25 of 25
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/immune-thrombocytopenia

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 25 of those studies listing the condition Immune Thrombocytopenia.

How many Immune Thrombocytopenia trials are recruiting in China?

18 of the 25 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 4 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Immune Thrombocytopenia), 25 studies
PhaseStudiesRecruitingShare
Phase 2171368%
Phase 1218%
Phase 3208%
Observational114%
Phase 1/2114%
Phase 2/3114%
Phase EARLY_PHASE1114%

Most active sponsors

Lead sponsors with the most studies (Immune Thrombocytopenia)
Lead sponsorStudiesRecruiting
Institute of Hematology & Blood Diseases Hospital, China1513
Peking University People's Hospital31
Chinese SLE Treatment And Research Group11
Guangdong Hengrui Pharmaceutical Co., Ltd11
Jian Zhu10
Peking Union Medical College Hospital11
Principia Biopharma, a Sanofi Company10
Shandong University10
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.